+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy in patients aged 12 to 65 who have mild to moderate rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, caused by sensitivity to grass and olive pollen. This randomized, double-blind, placebo-controlled phase 3 trial aims to study allergy treatments to improve symptoms and reduce medication use over one year. Participants are randomly assigned to one of three groups one receiving 10,000 TUmL MG01 plus 10,000 TUmL T517, another receiving 30,000 TUmL MG01 plus 10,000 TUmL T517, and a placebo group receiving the same solution without active ingredients. The allergen extracts come from a mixture of grasses and olive pollen, administered through subcutaneous injections. Treatment lasts for one year, evaluating different doses compared to placebo. During the study, participants will regularly record symptoms and medication use using a smartphone app. Researchers will monitor combined symptoms and medication scores as the primary outcome, along with medication-free days, symptom-free days, asthma exacerbations, quality of life tests for rhinitis and asthma, and immune response measures. Safety is closely followed through adverse reaction monitoring and immunological and security parameters over the 12-month treatment period.

Age: 12Years - 65YearsAll GendersPhase 3
32 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of subcutaneous immunotherapy in patients aged 12 to 65 who have rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, and who are sensitive to cupressaceae and grass pollen. This phase 3, multicenter, randomized, double-blinded, placebo-controlled trial aims to better understand treatment options for allergy symptoms related to these pollens. Participants will be randomly assigned to one of three groups two groups receiving different doses of a purified and polymerized allergen extract from grasses and cupressaceae mixed with aluminum hydroxide, and one placebo group receiving a similar solution without active ingredients. The treatment will be given by subcutaneous injections and will last for 18 months. The study will monitor symptoms and medication use during the specific pollen seasons for cupressaceae January to March and grasses May to June. Throughout the trial, participants will record their symptoms and medication intake using an electronic diary via a smartphone. Researchers will assess combined symptom and medication scores as the primary outcome, along with various secondary measures such as symptom-free days, medication-free days, asthma and rhinitis symptom scores, quality of life, immunological parameters, and safety. The total participation time for each subject is 18 months, during which their health and response to treatment will be closely monitored.

Age: 12Years - 65YearsAll GendersPhase 3
27 locations
L

Actively Recruiting

Researchers are conducting a multicenter observational study to gather long-term information from patients diagnosed with early-stage invasive breast cancer. These patients have previously participated in neoadjuvant or adjuvant clinical trials conducted by the GEICAM group. The study aims to provide data on the long-term outcomes and sequelae related to breast cancer treatments beyond the original trial follow-up periods. Participants are included after completing follow-up in their original GEICAM clinical trials and will be observed for approximately 30 years. This extended observation allows for evaluation of event-free survival and disease-free survival over a long duration. The study collects ongoing data without providing additional interventions. During the study, participants will be monitored through data collection related to survival outcomes, including overall survival, event-free survival, and disease-free survival. This long-term follow-up provides valuable information for healthcare professionals, patients, and society regarding the evolution and management of early-stage invasive breast cancer. Participation involves no new treatment, only data collection over many years.

Age: 18Years +FEMALE
73 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Age: 18Years +All Genders
84 locations
T

Actively Recruiting

Researchers are studying adults aged 18 to 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ph-negative ALL. The study evaluates treatment outcomes based on measurable residual disease MRD status and genetic testing done at the start. The goal is to tailor therapy after initial consolidation to improve survival and remission rates. Patients initially receive a four-drug induction chemotherapy regimen including vincristine, prednisone, pegylated asparaginase, and daunorubicin. Those who do not respond may receive a second induction with fludarabine, cytarabine, G-CSF, and idarubicin. Patients with good MRD clearance and favorable genetics continue with early and delayed consolidation, reinduction, and maintenance chemotherapy using pediatric-type protocols. Others may proceed to allogeneic hematopoietic stem cell transplantation alloHSCT. Participants will undergo regular assessments of MRD after induction and consolidation phases, along with monitoring for complete remission at 4 to 8 weeks. Researchers will track overall survival for 3 years. Safety and treatment responses are evaluated throughout, with ongoing follow-up. The total study duration includes treatment periods and observation to assess long-term outcomes under the guidance of the PETHEMA Foundation.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
108 locations